Camurus’ R&D Receives Boost As Novartis Exercises Octreotide Option
This article was originally published in The Pink Sheet Daily
The race to develop an easier-to-administer and less painful injection of octreotide for acromegaly is getting hotter, as Novartis takes over development of the Swedish company’s novel subcutaneous long-acting octreotide formulation.
You may also be interested in...
Following its approval in Europe earlier in 2012, the FDA approval of Signifor for Cushing’s disease is just the latest piece of a strategy to bring the injectable to market in multiple indications, including acromegaly.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Two European pharmaceutical companies, UCB and Merck KGaA, are exploring artificial intelligence in different ways, the first for drug discovery and the second on a fundamental level.